Elevance Health opened higher at $425.00, compared with its previous close of $422.02. In the last trading session, the stock traded between $416.47 and $426.77. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Elevance Health is now worth
$ 88.42
resulting in a loss of
$ 11.58 (11.58%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 14 Analysts
Buy
64.29%
Hold
35.71%
Sell
0%
Markets Today
Today's Change
$-3.70 (-0.88%)
Day High
$426.77
Day Low
$416.47
Day Open
$425.00
Prev Close
$422.02
Volume
4,11,676
1W Return
-6.08%
1M Return
6.50%
3M Return
11.23%
6M Return
11.07%
1Y Return
24.37%
Fundamentals
Market Cap ($ Mn)
90,380
PE Ratio
17.46
PB Ratio
1.91
PEG Ratio
3.02
ROE
13.14%
ROCE
-
EPS (TTM)
$6.29
Investment Returns
1 Week
-6.08%
1 Month
6.50%
3 Months
11.23%
6 Months
11.07%
9 Months
20.56%
Financials
Quarterly
All values in $ Mn
49.8K
Jun 25
50.7K
Sep 25
49.7K
Dec 25
50.2K
Mar 26
50.5K
Jun 26
51.4K
Sep 26
Updates
21Oct
Elevance Health raises 2026 guidance, targets 12% EPS growth for 2027
Adjusted diluted EPS rose to $6.99 in Q3FY26, beating analyst estimates. Full-year 2026 adjusted EPS guidance raised to at least $29.00. Company targets at least 12% adjusted EPS growth for fiscal year 2027. Medicaid margins expected to improve in 2027 due to favorable state rate actions. Carelon segment operating gain increased 17% YoY to $0.9 billion.
9 days ago
11Sep
Elevance Health reaffirms FY26 EPS guidance, shares rise 5%
Elevance Health reaffirmed FY26 adjusted EPS floor of $20.10, below $20.26 consensus. Underlying adjusted earnings projected above $27.00, beating $26.91 estimate. Benefit expense ratio target held at 90.2% with 0.5% tolerance. Shares rose 5.42% to $418.41 amid positive technical setup.
1mo ago
31Jul
Elevance Health cuts chemo hospital admissions by 66% with care model
Elevance Health’s Cancer Care Engagement program reduced chemotherapy-related hospital admissions by 66% and 30-day readmissions by 25%. With an 84% patient engagement rate, the model uses predictive analytics and oncology navigators to support 1.8 million annual U.S. cancer diagnoses. Provider partnerships further enhance treatment consistency and reduce waste.
3mo ago
17Jul
Analysts raise Elevance Health targets
Baird, RBC Capital, Cantor Fitzgerald, and Leerink Partners have all raised their price targets for Elevance Health, reflecting a positive revised valuation outlook.
3mo ago
16Jul
RBC lowers Elevance Health target to $424
RBC Capital analyst Ben Hendrix maintained a Sector Perform rating on Elevance Health while lowering the price target to $424 from $439. This adjustment contrasts with recent bullish revisions from TD Cowen, Truist Securities, and Wells Fargo, though Barclays also lowered its target to $457.
3mo ago
16Jul
Wells Fargo maintains Overweight on Elevance Health, lowers target to $473
Elevance Health reported Q2 2026 results beating estimates, with adjusted EPS of $7.45 and revenue of $49.826 billion, prompting a raise in full-year guidance. Wells Fargo analyst Stephen Baxter maintained an Overweight rating but lowered the price target to $473.
